Abraxis BioScience (ABBI) Tops Q2 EPS by 5c, Revs Light
More News related to ABBI
- Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
- Abraxis BioScience (ABBI) Tops Q2 EPS by 5c, Revs Light
- Abraxis BioScience (ABBI) Acquires Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates from Buck Institute
Abraxis BioScience, Inc. (NASDAQ: ABBI) reports Q2 adjusted EPS of $0.26, 5 cents better than estimates. Revenues were $242.5 million vs. $245.69 million consensus.
ABRAXANE revenue for the second quarter of 2007 increased 116.7 percent to $78.7 million, which included $69.6 million of net sales, versus revenue of $36.3 million in the same period of 2006.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
